All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
115 results for "Cancer" and "Gastrointestinal Cancers"
MRI-ENHANCE MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
This project is being done to to test an experimental treatment for your rectal adenocarcinoma called Magnetic Resonanceguided Adaptive Radiation Therapy in addition to the standard radiation therapy for your type of cancer.
Protocol No
IIT-HALL-MRI-ENHANCE
Sub Category
Transdermal Buprenorphine for the Treatment of Radiation Induced Mucositis Pain in Head & Neck Cancer Patients: A Pilot Study
Transdermal buprenorphine for the treatment of radiation induced mucositis pain in head & neck cancer patients: A pilot study
Protocol No
IIT-SHREENIVAS-BUPRENORPHINE
Sub Category
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
Protocol No
IIT-AWAN-NIH-DEHART
Sub Category
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination with Chemoradiation in Patients with Pancreatic Adenocarcinoma
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Protocol No
IIT-KAMGAR-CPI-613
Sub Category
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152-ALL
Sub Category
A First-in-Human, Phase 1-2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Sub Category
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma
Protocol No
TRANSTHERA-TT420C1206
Sub Category
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety & Efficacy of Magrolimab vs Placebo in Combination w/ Venetoclax & Azacitidine in Newly Diagnosed, Previously Untreated Patients w/ AML Who Are Ineligible for Intensive Chemotherapy
Magrolimab vs Placebo plus Venetoclax and Azacitidine in AML
Protocol No
GILEAD-GS-US-590-6154-AML
Sub Category
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Protocol No
ADP-0044-002-SPEARHEAD-1
Sub Category
A Randomized 3-arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old with Untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Protocol No
CARSGEN-CT041-ST-02
Sub Category
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
HLA-Mismatched Unrelated Donor HCT with Post-Transplantation Cyclophosphamide (Access)
Protocol No
NMDP-ACCESS
Sub Category
An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib Plus Cetuximab with or without Chemotherapy Versus Standard of Care Therapy with a Safety Lead-In of Encorafenib and Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Protocol No
PFIZER-C4221015-BREAKWATER
Sub Category
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
AlloVir P-106-001 Study in Patients Developing Respiratory Infections Post HSCT
Protocol No
ALLOVIR-P-106-001-RESP
Sub Category
A Phase 1b/2a, Open-label, Dose-escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
To assess the safety of STI-6129 in patients with relapse refractory (AL) Amyloidosis. To assess the efficacy of STI-6129 in the treatment of patients with R/R systemic AL Amyloidosis.
Protocol No
SORRENTO-STI-6129-001
GILEAD-GS-US-546-5857-AML: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Venetoclax plus Azacitidine in Previously Untreated Patients with TP53 Mutant AML who are Ineligible for Intensive Induction Chemotherapy
Magrolimab plus Azacitidine vs Venetoclax plus Azacitidine in Previously Untreated TP53 Mutant AML
Protocol No
GILEAD-GS-US-546-5857-AML
Sub Category
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients with Soft Tissue Sarcoma - CEP-2
To estimate the maximum tolerated dose (MTD) of NOX66 in combination with doxorubicin. To characterize the safety and tolerability of NOX66 alone and in combination with doxorubicin.
Protocol No
NOXOPHARM-NOX66-004
Sub Category
A Phase 1/2 dose escalation and dose expansion study of BA3011 alone and in combination with Nivolumab in adult and adolescent patients 12 years and older with advanced solid tumors
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.
Protocol No
BIOATLA-BA3011-001
Sub Category
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 MG/M2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 MG/M2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Comparing high-dose cisplatin every three weeks to low-dose cisplatin weekly when combined with radiation for patients with advanced head and neck cancer
Protocol No
NRG-HN009
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category